Țară: Canada
Limbă: engleză
Sursă: Health Canada
CEFEPIME (CEFEPIME HYDROCHLORIDE)
QILU PHARMACEUTICAL CO., LTD.
J01DE01
CEFEPIME
2G
POWDER FOR SOLUTION
CEFEPIME (CEFEPIME HYDROCHLORIDE) 2G
INTRAVENOUS
20ML
Prescription
FOURTH GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0150504005; AHFS:
APPROVED
2017-05-17
Page 1 of 40 PRODUCT MONOGRAPH Pr Cefepime for Injection, USP (cefepime hydrochloride for injection) 1 g and 2 g cefepime per vial (as cefepime hydrochloride) Antibiotic _ _ _DIN OWNER / MANUFACTURED BY:_ DATE OF PREPARATION: Qilu Pharmaceutical Co., Ltd. May 11, 2017 No. 243 Gong Ye Bei Road Jinan, 250100, China _IMPORTED BY / DISTRIBUTED BY: _DATE OF REVISION:_ _ Apotex Inc. August 9, 2019 4100 Weston Road Toronto, Ontario Canada, M9L 2Y6 Control Number: 216756 Page 2 of 40 _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE .................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 5 WARNINGS AND PRECAUTIONS ........................................................................................ 5 ADVERSE REACTIONS .......................................................................................................... 9 DRUG INTERACTIONS......................................................................................................... 10 DOSAGE AND ADMINISTRATION .................................................................................... 11 OVERDOSAGE ....................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 16 STORAGE AND STABILITY ................................................................................................ 19 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 20 PART II: SCIENTIFIC INFORMATION ...... Citiți documentul complet